363 related articles for article (PubMed ID: 30130293)
1. WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history.
Kingsberg SA; Larkin L; Krychman M; Parish SJ; Bernick B; Mirkin S
Menopause; 2019 Feb; 26(2):124-131. PubMed ID: 30130293
[TBL] [Abstract][Full Text] [Related]
2. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
Kingsberg SA; Wysocki S; Magnus L; Krychman ML
J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
[TBL] [Abstract][Full Text] [Related]
3. The Women's EMPOWER Survey: Women's Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate.
Krychman M; Graham S; Bernick B; Mirkin S; Kingsberg SA
J Sex Med; 2017 Mar; 14(3):425-433. PubMed ID: 28202319
[TBL] [Abstract][Full Text] [Related]
4. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.
Menopause; 2013 Sep; 20(9):888-902; quiz 903-4. PubMed ID: 23985562
[TBL] [Abstract][Full Text] [Related]
5. The Women's EMPOWER Survey: Identifying Women's Perceptions on Vulvar and Vaginal Atrophy and Its Treatment.
Kingsberg SA; Krychman M; Graham S; Bernick B; Mirkin S
J Sex Med; 2017 Mar; 14(3):413-424. PubMed ID: 28202320
[TBL] [Abstract][Full Text] [Related]
6. Local ultra-low-dose estriol gel treatment of vulvo-vaginal atrophy: efficacy and safety of long-term treatment.
Villa P; Tagliaferri V; Amar ID; Cipolla C; Ingravalle F; Scambia G; Ricciardi W; Lanzone A
Gynecol Endocrinol; 2020 Jun; 36(6):535-539. PubMed ID: 31847628
[TBL] [Abstract][Full Text] [Related]
7. Attitudes and perceptions towards vulvar and vaginal atrophy in Italian post-menopausal women: Evidence from the European REVIVE survey.
Nappi RE; Particco M; Biglia N; Cagnacci A; Di Carlo C; Luisi S; Paoletti AM
Maturitas; 2016 Sep; 91():74-80. PubMed ID: 27451324
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol.
Pickar JH; Amadio JM; Hill JM; Bernick BA; Mirkin S
Menopause; 2016 May; 23(5):506-10. PubMed ID: 26836245
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study.
De Seta F; Caruso S; Di Lorenzo G; Romano F; Mirandola M; Nappi RE
Maturitas; 2021 May; 147():34-40. PubMed ID: 33832645
[TBL] [Abstract][Full Text] [Related]
10. Vaginal Atrophy in Breast Cancer Survivors: Attitude and Approaches Among Oncologists.
Biglia N; Bounous VE; D'Alonzo M; Ottino L; Tuninetti V; Robba E; Perrone T
Clin Breast Cancer; 2017 Dec; 17(8):611-617. PubMed ID: 28655486
[TBL] [Abstract][Full Text] [Related]
11. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
Pinkerton JV; Stanczyk FZ
Menopause; 2014 Mar; 21(3):309-19. PubMed ID: 23777900
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
[TBL] [Abstract][Full Text] [Related]
13. Macro-regional variation in attitudes toward and experiences of vulvar and vaginal atrophy among Italian post-menopausal women: a post hoc analysis of REVIVE survey data.
Nappi RE; Particco M; Biglia N; Cagnacci A; Di Carlo C; Luisi S; Paoletti AM
Gynecol Endocrinol; 2017 May; 33(5):389-394. PubMed ID: 28277131
[TBL] [Abstract][Full Text] [Related]
14. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.
Nappi RE; Palacios S; Panay N; Particco M; Krychman ML
Climacteric; 2016 Apr; 19(2):188-97. PubMed ID: 26581580
[TBL] [Abstract][Full Text] [Related]
15. Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease.
Pérez-López FR; Phillips N; Vieira-Baptista P; Cohen-Sacher B; Fialho SCAV; Stockdale CK
Gynecol Endocrinol; 2021 Aug; 37(8):746-752. PubMed ID: 34169794
[TBL] [Abstract][Full Text] [Related]
16. Estradiol softgel inserts for the treatment of VVA symptoms: an expert opinion.
Liu JH; Bernick B; Mirkin S
Expert Opin Drug Deliv; 2020 Nov; 17(11):1573-1581. PubMed ID: 32877254
[TBL] [Abstract][Full Text] [Related]
17. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial.
Paraiso MFR; Ferrando CA; Sokol ER; Rardin CR; Matthews CA; Karram MM; Iglesia CB
Menopause; 2020 Jan; 27(1):50-56. PubMed ID: 31574047
[TBL] [Abstract][Full Text] [Related]
18. Incidence of genitourinary conditions in women with a diagnosis of vulvar/vaginal atrophy.
Constantine GD; Bruyniks N; Princic N; Huse D; Palmer L; Lenhart G; Blumentals WA; Nappi RE
Curr Med Res Opin; 2014 Jan; 30(1):143-8. PubMed ID: 24083677
[TBL] [Abstract][Full Text] [Related]
19. Pelvic floor muscles training to reduce symptoms and signs of vulvovaginal atrophy: a case study.
Mercier J; Morin M; Lemieux MC; Reichetzer B; Khalifé S; Dumoulin C
Menopause; 2016 Jul; 23(7):816-20. PubMed ID: 27219835
[TBL] [Abstract][Full Text] [Related]
20. Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perceptions.
Palacios S; Cancelo MJ; Castelo Branco C; Llaneza P; Molero F; Borrego RS
Climacteric; 2017 Feb; 20(1):55-61. PubMed ID: 28042734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
